AstraZeneca PLC (AZN.L)
6 Dec 2013
|Market Cap (Mil.):||£43,693.64|
|Shares Outstanding (Mil.):||1,255.42|
Dec 6 - AstraZeneca PLC : * European Commission approves intranasal four-strain influenza vaccine Fluenz Tetra * Follows a positive opinion from the Committee for Medicinal Products for Human Use on 19 September 2013 * Source text for Eikon: * For more news, please click here
NEW YORK - A U.S. federal judge has awarded AstraZeneca Plc $76 million in damages from generic drug manufacturer Apotex for infringing upon patents for AstraZeneca's blockbuster heartburn drug, Prilosec, between 2003 and 2007.
NEW YORK, Dec 3 - A U.S. federal judge has awarded AstraZeneca Plc $76 million in damages from generic drug manufacturer Apotex for infringing upon patents for AstraZeneca's blockbuster heartburn drug, Prilosec, between 2003 and 2007.
Nov 22 - (The following statement was released by the rating agency)
ZURICH - Shares in Swiss biotech company Actelion rose on Thursday after broker Citi said in a research note British pharma group AstraZeneca might be interested in buying it.
- Horizon Pharma Inc said it would buy the right to market AstraZeneca Plc's arthritis drug Vimovo in the United States for an upfront payment of $35 million, sending up its shares 24 percent in premarket trading.
Nov 19 - Horizon Pharma Inc : * Announces agreement to acquire U.S. rights to Vimovo(R) and provides 2014
Nov 19 - AstraZeneca PLC : * New drug application for Naloxegol accepted by U.S. FDA * Will make a $70 million milestone payment to Nektar within five business days of acceptance of the NDA by the FDA * Source text for Eikon: * For more news, please click here
LONDON, Nov 11 - AstraZeneca said on Monday it would invest 120 million pounds ($190 million) in a new facility at its global manufacturing site in Macclesfield, northern England, to continue production of prostate cancer drug Zoladex.
LONDON - AstraZeneca may seek to increase its stake in a diabetes joint venture with Bristol-Myers Squibb, following a decision by the U.S. firm to exit diabetes drug research, according to Citi.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
"The Economy Matters" Report for AZN: the economy's impact on AZN's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: S&P Capital IQ – STARS Reports
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.